CGEM Cullinan Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Cullinan Therapeutics Inc reported revenue of n/a, net income of −$53.7M and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was n/a.
CGEM annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$242M, net income −$220M (margin n/a), EPS n/a
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$197M, net income −$168M (margin n/a), EPS n/a
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$191M, net income −$155M (margin n/a), EPS −$3.69
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income $145M, net income $111M (margin n/a), EPS $2.38
- Fiscal year ended Dec 2021: revenue $18.9M, gross profit n/a, operating income −$68.0M, net income −$65.6M (margin -346.1%), EPS −$1.52
CGEM quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$53.7M, EPS n/a
- Quarter ended Mar 31, 2026: revenue n/a, net income −$49.7M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$50.7M, EPS n/a
- Quarter ended Sep 30, 2025: revenue n/a, net income −$50.6M, EPS n/a
- Quarter ended Jun 30, 2025: revenue n/a, net income −$70.1M, EPS n/a
- Quarter ended Mar 31, 2025: revenue n/a, net income −$48.5M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$47.8M, EPS n/a
- Quarter ended Sep 30, 2024: revenue n/a, net income −$40.6M, EPS −$0.69
- Quarter ended Jun 30, 2024: revenue n/a, net income −$42.0M, EPS −$0.75
- Quarter ended Mar 31, 2024: revenue n/a, net income −$37.1M, EPS −$0.86
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$25.7M, EPS −$0.54
- Quarter ended Sep 30, 2023: revenue n/a, net income −$39.2M, EPS −$0.91
- Quarter ended Jun 30, 2023: revenue n/a, net income −$32.2M, EPS −$0.82
- Quarter ended Mar 31, 2023: revenue n/a, net income −$58.0M, EPS −$1.42
- Quarter ended Dec 31, 2022 (from the annual report): revenue $0, net income −$26.8M, EPS −$0.58
- Quarter ended Sep 30, 2022: revenue $0, net income −$24.8M, EPS −$0.54
- Quarter ended Jun 30, 2022: revenue $0, net income $175M, EPS $3.77
- Quarter ended Mar 31, 2022: revenue $0 (down 100.0% year over year), net income −$12.1M, EPS −$0.27
- Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$32.5M, EPS −$0.76
- Quarter ended Sep 30, 2021: revenue $0, net income −$17.4M, EPS −$0.40
CGEM cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$176M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$145M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$134M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$127M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$43.4M, share buybacks n/a
CGEM balance sheet
- Jun 30, 2026: cash $78.6M, total assets $364M, total liabilities $42.0M, shareholders' equity n/a
- Mar 31, 2026: cash $75.1M, total assets $403M, total liabilities $36.8M, shareholders' equity n/a
- Dec 31, 2025: cash $88.3M, total assets $448M, total liabilities $39.6M, shareholders' equity $409M
- Sep 30, 2025: cash $103M, total assets $484M, total liabilities $32.8M, shareholders' equity $451M
- Jun 30, 2025: cash $72.8M, total assets $520M, total liabilities $28.2M, shareholders' equity $492M
- Mar 31, 2025: cash $76.7M, total assets $580M, total liabilities $27.8M, shareholders' equity $552M
- Dec 31, 2024: cash $83.0M, total assets $622M, total liabilities $31.5M, shareholders' equity $590M
- Sep 30, 2024: cash $102M, total assets $653M, total liabilities $25.4M, shareholders' equity $628M
Is CGEM profitable?
No. Cullinan Therapeutics Inc lost $205M over the last four quarters.